GB201707561D0 - GARP-TGF-beta antibodies - Google Patents

GARP-TGF-beta antibodies

Info

Publication number
GB201707561D0
GB201707561D0 GBGB1707561.5A GB201707561A GB201707561D0 GB 201707561 D0 GB201707561 D0 GB 201707561D0 GB 201707561 A GB201707561 A GB 201707561A GB 201707561 D0 GB201707561 D0 GB 201707561D0
Authority
GB
United Kingdom
Prior art keywords
garp
tgf
beta antibodies
antibodies
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1707561.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX BVBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX BVBA filed Critical ArgenX BVBA
Priority to GBGB1707561.5A priority Critical patent/GB201707561D0/en
Publication of GB201707561D0 publication Critical patent/GB201707561D0/en
Priority to PE2019002382A priority patent/PE20200618A1/es
Priority to EP18728524.2A priority patent/EP3606961B8/en
Priority to US15/977,449 priority patent/US10479829B2/en
Priority to IL305613A priority patent/IL305613A/en
Priority to KR1020247014708A priority patent/KR20240065192A/ko
Priority to UAA201911783A priority patent/UA125534C2/uk
Priority to LTEPPCT/EP2018/062251T priority patent/LT3606961T/lt
Priority to PCT/EP2018/062251 priority patent/WO2018206790A1/en
Priority to SM20220284T priority patent/SMT202200284T1/it
Priority to DK18728524.2T priority patent/DK3606961T3/da
Priority to CR20190561A priority patent/CR20190561A/es
Priority to BR112019023735A priority patent/BR112019023735A8/pt
Priority to NZ758647A priority patent/NZ758647A/en
Priority to AU2018265241A priority patent/AU2018265241B2/en
Priority to EP23189977.4A priority patent/EP4282430A3/en
Priority to SI201830702T priority patent/SI3606961T1/sl
Priority to RU2019140602A priority patent/RU2767784C2/ru
Priority to SG10201914130VA priority patent/SG10201914130VA/en
Priority to CA3061841A priority patent/CA3061841C/en
Priority to MYPI2019006528A priority patent/MY199335A/en
Priority to ES18728524T priority patent/ES2921015T3/es
Priority to HRP20220787TT priority patent/HRP20220787T1/hr
Priority to JP2020512919A priority patent/JP7118135B2/ja
Priority to PT187285242T priority patent/PT3606961T/pt
Priority to HUE18728524A priority patent/HUE059237T2/hu
Priority to EP22168997.9A priority patent/EP4086286A1/en
Priority to CN201880046262.8A priority patent/CN110945027B/zh
Priority to MX2019013490A priority patent/MX385670B/es
Priority to IL270236A priority patent/IL270236B2/en
Priority to PL18728524.2T priority patent/PL3606961T3/pl
Priority to KR1020197036577A priority patent/KR102664663B1/ko
Priority to RS20220600A priority patent/RS63361B1/sr
Priority to US16/409,679 priority patent/US10875914B2/en
Priority to DO2019000285A priority patent/DOP2019000285A/es
Priority to CL2019003211A priority patent/CL2019003211A1/es
Priority to PH12019502526A priority patent/PH12019502526A1/en
Priority to US16/698,833 priority patent/US10793627B2/en
Priority to CONC2019/0013669A priority patent/CO2019013669A2/es
Priority to ECSENADI201987742A priority patent/ECSP19087742A/es
Priority to US17/096,931 priority patent/US20210324061A1/en
Priority to AU2021240255A priority patent/AU2021240255A1/en
Priority to CY20221100444T priority patent/CY1125674T1/el
Priority to JP2022122483A priority patent/JP2022169549A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
GBGB1707561.5A 2017-05-11 2017-05-11 GARP-TGF-beta antibodies Ceased GB201707561D0 (en)

Priority Applications (44)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
RS20220600A RS63361B1 (sr) 2017-05-11 2018-05-11 Garp-tgf-beta antitela
MYPI2019006528A MY199335A (en) 2017-05-11 2018-05-11 Garp-tgf- antibodies
EP18728524.2A EP3606961B8 (en) 2017-05-11 2018-05-11 Garp-tgf-beta antibodies
US15/977,449 US10479829B2 (en) 2017-05-11 2018-05-11 GARP-TGF-beta 1 antibodies
IL305613A IL305613A (en) 2017-05-11 2018-05-11 Antibodies TGF – GARP beta
KR1020247014708A KR20240065192A (ko) 2017-05-11 2018-05-11 GARP-TGF-β 항체
UAA201911783A UA125534C2 (uk) 2017-05-11 2018-05-11 АНТИ-GARP-TGF-<font face="Symbol">b</font>-АНТИТІЛО
LTEPPCT/EP2018/062251T LT3606961T (lt) 2017-05-11 2018-05-11 Garp-tgf-beta antikūnai
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES
SM20220284T SMT202200284T1 (it) 2017-05-11 2018-05-11 Anticorpi garp-tgf-beta
DK18728524.2T DK3606961T3 (da) 2017-05-11 2018-05-11 Garp-tgf-beta-antistoffer
CR20190561A CR20190561A (es) 2017-05-11 2018-05-11 ANTICUERPOS ANTI-GARP-TGF-ß
BR112019023735A BR112019023735A8 (pt) 2017-05-11 2018-05-11 Anticorpos de garp-tgf-ss
NZ758647A NZ758647A (en) 2017-05-11 2018-05-11 Garp-tgf-β antibodies
AU2018265241A AU2018265241B2 (en) 2017-05-11 2018-05-11 GARP-TGF-β antibodies
EP23189977.4A EP4282430A3 (en) 2017-05-11 2018-05-11 Garp-tgf-beta antibodies
SI201830702T SI3606961T1 (sl) 2017-05-11 2018-05-11 Protitelesa garp-tgf-beta
RU2019140602A RU2767784C2 (ru) 2017-05-11 2018-05-11 АНТИ-GARP-TGF-β-АНТИТЕЛА
SG10201914130VA SG10201914130VA (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES
CA3061841A CA3061841C (en) 2017-05-11 2018-05-11 Garp-tgf-.beta. antibodies
PE2019002382A PE20200618A1 (es) 2017-05-11 2018-05-11 ANTICUERPOS ANTI-GARP-TGF-Beta1
HRP20220787TT HRP20220787T1 (hr) 2017-05-11 2018-05-11 Protutijela protiv garp-tgf-beta
JP2020512919A JP7118135B2 (ja) 2017-05-11 2018-05-11 ＧＡＲＰ－ＴＧＦ－β抗体
ES18728524T ES2921015T3 (es) 2017-05-11 2018-05-11 Anticuerpos contra GARP-TGF-BETA
PT187285242T PT3606961T (pt) 2017-05-11 2018-05-11 Anticorpos garp-tgf-beta
HUE18728524A HUE059237T2 (hu) 2017-05-11 2018-05-11 GARP-TGF-béta antitestek
EP22168997.9A EP4086286A1 (en) 2017-05-11 2018-05-11 Garp-tgf-beta antibodies
CN201880046262.8A CN110945027B (zh) 2017-05-11 2018-05-11 GARP-TGF-β抗体
MX2019013490A MX385670B (es) 2017-05-11 2018-05-11 Anticuerpos anti-garp-tgf-b.
IL270236A IL270236B2 (en) 2017-05-11 2018-05-11 Antibodies GARP – TGF beta
PL18728524.2T PL3606961T3 (pl) 2017-05-11 2018-05-11 Przeciwciała garp-tgf-beta
KR1020197036577A KR102664663B1 (ko) 2017-05-11 2018-05-11 GARP-TGF-β 항체
US16/409,679 US10875914B2 (en) 2017-05-11 2019-05-10 Nucleic acids encoding GARP-TGF-beta 1 antibodies
DO2019000285A DOP2019000285A (es) 2017-05-11 2019-11-08 ANTICUERPOS ANTI-GARP-TGF-ß
CL2019003211A CL2019003211A1 (es) 2017-05-11 2019-11-08 Anticuerpos anti-garp-tgf-ß.
PH12019502526A PH12019502526A1 (en) 2017-05-11 2019-11-11 GARP-TGF-á ANTIBODIES
US16/698,833 US10793627B2 (en) 2017-05-11 2019-11-27 GARP-TGF-β 1 IGG antibodies
CONC2019/0013669A CO2019013669A2 (es) 2017-05-11 2019-12-04 Anticuerpos anti-garp-tgf-β
ECSENADI201987742A ECSP19087742A (es) 2017-05-11 2019-12-10 Anticuerpos anti-garp-tgf-b
US17/096,931 US20210324061A1 (en) 2017-05-11 2020-11-12 Garp-tgf-beta antibodies
AU2021240255A AU2021240255A1 (en) 2017-05-11 2021-09-30 GARP-TGF-ß antibodies
CY20221100444T CY1125674T1 (el) 2017-05-11 2022-06-29 Αντισωματα garp-tgf-bhta
JP2022122483A JP2022169549A (ja) 2017-05-11 2022-08-01 ＧＡＲＰ－ＴＧＦ－β抗体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies

Publications (1)

Publication Number Publication Date
GB201707561D0 true GB201707561D0 (en) 2017-06-28

Family

ID=59201573

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1707561.5A Ceased GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies

Country Status (35)

Country Link
US (4) US10479829B2 (enExample)
EP (3) EP4086286A1 (enExample)
JP (2) JP7118135B2 (enExample)
KR (2) KR20240065192A (enExample)
CN (1) CN110945027B (enExample)
AU (2) AU2018265241B2 (enExample)
BR (1) BR112019023735A8 (enExample)
CA (1) CA3061841C (enExample)
CL (1) CL2019003211A1 (enExample)
CO (1) CO2019013669A2 (enExample)
CR (1) CR20190561A (enExample)
CY (1) CY1125674T1 (enExample)
DK (1) DK3606961T3 (enExample)
DO (1) DOP2019000285A (enExample)
EC (1) ECSP19087742A (enExample)
ES (1) ES2921015T3 (enExample)
GB (1) GB201707561D0 (enExample)
HR (1) HRP20220787T1 (enExample)
HU (1) HUE059237T2 (enExample)
IL (2) IL270236B2 (enExample)
LT (1) LT3606961T (enExample)
MX (1) MX385670B (enExample)
MY (1) MY199335A (enExample)
NZ (1) NZ758647A (enExample)
PE (1) PE20200618A1 (enExample)
PH (1) PH12019502526A1 (enExample)
PL (1) PL3606961T3 (enExample)
PT (1) PT3606961T (enExample)
RS (1) RS63361B1 (enExample)
RU (1) RU2767784C2 (enExample)
SG (1) SG10201914130VA (enExample)
SI (1) SI3606961T1 (enExample)
SM (1) SMT202200284T1 (enExample)
UA (1) UA125534C2 (enExample)
WO (1) WO2018206790A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
KR20250093432A (ko) 2019-08-28 2025-06-24 추가이 세이야쿠 가부시키가이샤 종교차성 항잠재형 TGF-β1 항체 및 사용 방법
JPWO2021079958A1 (enExample) 2019-10-25 2021-04-29
TW202135862A (zh) * 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
WO2021167703A1 (en) 2020-02-19 2021-08-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof
WO2021231732A1 (en) * 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
AU2021380681A1 (en) * 2020-11-11 2023-06-15 Versapeutics Inc. Antibody variants against wnt receptor ryk
IL303349A (en) * 2020-12-02 2023-08-01 Shanghai Henlius Biotech Inc ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE
BR112023014319A2 (pt) * 2021-01-18 2023-09-26 Jiangxi Jemincare Group Co Ltd Anticorpo contra a proteína garp e aplicação do mesmo
WO2023225555A1 (en) 2022-05-18 2023-11-23 Vestaron Corporation Pesticidal actx peptide variants
JP2025526336A (ja) 2022-07-22 2025-08-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｔ細胞悪性腫瘍におけるバイオマーカー及びバイオターゲットとしてのｇａｒｐ
EP4561612A1 (en) 2022-07-29 2025-06-04 Abbvie Biotherapeutics Inc. Anti-garp-tgf-beta1/pd-1 combination therapy
KR20250133913A (ko) 2023-01-09 2025-09-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8951793B2 (en) 2008-08-21 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of making an isolated population of FOXP3+ regulatory T cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
WO2014033252A1 (en) 2012-08-31 2014-03-06 arGEN-X BV Method for producing antibody molecules having inter-species, intra-target cross-reactivity
EP2981822B1 (en) 2013-05-06 2020-09-02 Scholar Rock, Inc. Compositions and methods for growth factor modulation
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
NZ717476A (en) 2013-08-01 2022-04-29 Univ Catholique Louvain Anti-garp protein and uses thereof
EP3253796A1 (en) 2015-02-03 2017-12-13 Université Catholique de Louvain Anti-garp protein and uses thereof
CN115869398B (zh) * 2015-09-24 2025-04-22 第一三共株式会社 抗garp抗体
CA3030862A1 (en) * 2016-07-14 2018-01-18 Scholar Rock, Inc. Tgfb antibodies, methods, and uses

Also Published As

Publication number Publication date
EP4282430A2 (en) 2023-11-29
KR20240065192A (ko) 2024-05-14
US20180327487A1 (en) 2018-11-15
PE20200618A1 (es) 2020-03-11
BR112019023735A2 (pt) 2020-06-09
CA3061841C (en) 2022-08-09
US20190375832A1 (en) 2019-12-12
US10479829B2 (en) 2019-11-19
WO2018206790A1 (en) 2018-11-15
CO2019013669A2 (es) 2020-04-01
AU2018265241B2 (en) 2021-11-04
MX385670B (es) 2025-03-18
RS63361B1 (sr) 2022-07-29
SI3606961T1 (sl) 2022-10-28
CR20190561A (es) 2020-04-04
US10793627B2 (en) 2020-10-06
IL270236B2 (en) 2024-02-01
EP4282430A3 (en) 2024-04-03
CN110945027B (zh) 2023-08-01
NZ758647A (en) 2022-07-29
JP2020519308A (ja) 2020-07-02
AU2021240255A1 (en) 2021-10-28
IL305613A (en) 2023-11-01
EP3606961B8 (en) 2022-07-13
ES2921015T3 (es) 2022-08-16
PH12019502526A1 (en) 2020-07-20
MX2019013490A (es) 2021-08-26
IL270236A (enExample) 2019-12-31
LT3606961T (lt) 2022-07-11
CY1125674T1 (el) 2025-05-09
ECSP19087742A (es) 2020-05-29
JP7118135B2 (ja) 2022-08-15
CN110945027A (zh) 2020-03-31
JP2022169549A (ja) 2022-11-09
CA3061841A1 (en) 2018-11-15
HRP20220787T1 (hr) 2022-09-16
US20210324061A1 (en) 2021-10-21
IL270236B1 (en) 2023-10-01
RU2767784C2 (ru) 2022-03-21
PT3606961T (pt) 2022-07-04
PL3606961T3 (pl) 2022-08-16
RU2019140602A3 (enExample) 2021-07-23
US20200095311A1 (en) 2020-03-26
KR102664663B1 (ko) 2024-05-23
HUE059237T2 (hu) 2022-11-28
SG10201914130VA (en) 2020-03-30
EP4086286A1 (en) 2022-11-09
BR112019023735A8 (pt) 2023-01-31
EP3606961B1 (en) 2022-06-01
CL2019003211A1 (es) 2020-04-24
UA125534C2 (uk) 2022-04-13
EP3606961A1 (en) 2020-02-12
MY199335A (en) 2023-10-24
KR20200027469A (ko) 2020-03-12
SMT202200284T1 (it) 2022-09-14
US10875914B2 (en) 2020-12-29
DOP2019000285A (es) 2020-07-15
DK3606961T3 (da) 2022-07-04
AU2018265241A1 (en) 2019-11-21
RU2019140602A (ru) 2021-06-11

Similar Documents

Publication Publication Date Title
IL268517A (en) Anti-tigit antibodies
ZA201905966B (en) Anti-lag3 antibodies
IL267797B1 (en) Anti-gpc3 antibody
SG11202000660QA (en) Anti-tigit antibodies
LT3625259T (lt) Anti-sirpalfa antikūnai
ZA202002141B (en) Anti-transthyretin antibodies
GB201709808D0 (en) Antibodies
IL273393A (en) New epsilon anti-CD3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201601073D0 (en) Antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB201610044D0 (en) Antibodies
GB201616699D0 (en) Antibodies
ZA202103456B (en) Anti-alpha-synuclein antibodies
GB201603291D0 (en) Antibodies
GB201720970D0 (en) Antibodies
IL271067A (en) Anti-trkb antibodies
IL273529A (en) Anti-PACAP antibody
PT3484921T (pt) Anticorpos anti-il-22r
GB201711785D0 (en) Antibodies
GB201717006D0 (en) Anti-OPG antibodies
GB201709818D0 (en) Antibodies
GB201703071D0 (en) Antibodies
GB201701416D0 (en) Anti-OPG antibodies
GB201709592D0 (en) Antibody

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)